Stave Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.95 M
as on 10-12-2024
- Revenue -27.88%
(FY 2020)
- Profit -237.25%
(FY 2020)
- Ebitda -118.25%
(FY 2020)
- Net Worth -17.21%
(FY 2020)
- Total Assets -5.09%
(FY 2020)
About Stave Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.95 M.
Ravi Kumar, Rajkumari Sinha, and Amrita Kumari serve as directors at the Company.
- CIN/LLPIN
U33100BR2008PTC013429
- Company No.
013429
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Feb 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Stave Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Kumar  | Managing Director | 13-Feb-2008 | Current |
| Rajkumari Sinha | Managing Director | 13-Feb-2008 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amrita Kumari | Director | 24-Jan-2024 | Current |
Financial Performance of Stave Pharmaceuticals.
Stave Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 27.88% decrease. The company also saw a substantial fall in profitability, with a 237.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stave Pharmaceuticals?
In 2018, Stave Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Apr 2020 | ₹0.45 M | Open |
Others Creation Date: 17 Mar 2011 | ₹4.50 M | Open |
How Many Employees Work at Stave Pharmaceuticals?
Stave Pharmaceuticals has a workforce of 6 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stave Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stave Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
